INT15367

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1982
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 35
Total Number 36
Disease Relevance 24.90
Pain Relevance 5.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (OPA1) mitochondrion organization (OPA1) GTPase activity (OPA1)
Anatomy Link Frequency
mandible 2
CPA 2
plasma 1
spinal cord 1
brain 1
OPA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 19 99.80 Very High Very High Very High
Migraine 34 99.04 Very High Very High Very High
transdermal 12 98.76 Very High Very High Very High
tolerance 10 98.46 Very High Very High Very High
anesthesia 26 96.12 Very High Very High Very High
adenocard 10 94.72 High High
peripheral neuropathy 64 94.68 High High
Spinal cord 8 92.28 High High
headache 32 91.36 High High
cva 162 88.88 High High
Disease Link Frequency Relevance Heat
Cancer 512 100.00 Very High Very High Very High
Disease 216 100.00 Very High Very High Very High
Low Tension Glaucoma 201 100.00 Very High Very High Very High
Glaucoma 160 100.00 Very High Very High Very High
Targeted Disruption 99 100.00 Very High Very High Very High
Mitochondrial Disorders 32 100.00 Very High Very High Very High
Residual Neoplasm 30 100.00 Very High Very High Very High
Angina 1 99.80 Very High Very High Very High
Retinal Vein Occlusion 231 99.68 Very High Very High Very High
Hypotension 18 99.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Identification of OPA1 mutations
Gene_expression (mutations) of OPA1
1) Confidence 0.67 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.06 Pain Relevance 0.03
In addition, we conducted a systematic review of the literature to identify other DOA+ families with confirmed OPA1 mutations.
Gene_expression (families) of OPA1
2) Confidence 0.67 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.39 Pain Relevance 0.03
The prevalence of non-insulin dependent diabetes in our DOA+ cohort (3.6%) was comparable to the latest UK national figures (3.9%) (NHS Quality and Outcomes Framework, 2008), and although severe, characteristic migrainous episodes were reported by 4 out of 83 (4.8%) patients with DOA+, this could simply reflect the background prevalence of migraine in the general population (11–15%), and not an OPA1-related effect per se (Goadsby et al., 2002; Bigal et al., 2006).


Gene_expression (effect) of OPA1-related associated with diabetes mellitus and migraine
3) Confidence 0.67 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.43 Pain Relevance 0.14
A recent unexpected addition to this list of genes linked to nuclear mitochondrial disorders was OPA1, the major causative gene in ?
Gene_expression (unexpected) of OPA1 associated with mitochondrial disorders
4) Confidence 0.67 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.94 Pain Relevance 0.07
Nitroglycerin (NTG) (glyceryl trinitrate) was synthesized by the Italian chemist Ascanio Sobrero in Paris in 1846.
Gene_expression (synthesized) of NTG
5) Confidence 0.66 Published 2009 Journal Headache Section Abstract Doc Link 19267787 Disease Relevance 0.30 Pain Relevance 0.36
NTG was introduced in 1879 in medicine in the treatment of angina pectoris by the English doctor William Murrell.
Gene_expression (introduced) of NTG associated with angina
6) Confidence 0.66 Published 2009 Journal Headache Section Abstract Doc Link 19267787 Disease Relevance 0.34 Pain Relevance 0.41
The data obtained show that NTG and PETN together significantly modify the expression of >1,600 genes (NTG 532, PETN 1212).
Gene_expression (expression) of NTG
7) Confidence 0.63 Published 2009 Journal Physiol. Genomics Section Abstract Doc Link 19417013 Disease Relevance 0.22 Pain Relevance 0.07
The heterogeneous multi-system manifestations seen in DOA+ families and the remarkable variable penetrance among carriers with the same pathogenic variant clearly implicate the influence of secondary modulatory factors on the phenotypic expression of the ‘primary’ OPA1 mutation.
Gene_expression (expression) of OPA1
8) Confidence 0.60 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.44 Pain Relevance 0
Novel OPA1 mutations
Gene_expression (mutations) of OPA1
9) Confidence 0.58 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.67 Pain Relevance 0
Prior to OPA1 screening, the probands were extensively investigated to establish the underlying cause for their spasticity, and these were all negative: cerebrospinal fluid (CSF) studies, metabolic screen, brain and spinal cord MRI, and SPG4 genetic testing.
Gene_expression (screening) of OPA1 in spinal cord associated with spasticity and spinal cord
10) Confidence 0.58 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 1.24 Pain Relevance 0.11
Peak exercise heart rate and pressure rate product were both significantly higher on TTS NTG, as well as on nifedipine, in comparison with placebo, while values after verapamil did not differ from those after placebo.
Gene_expression (higher) of NTG in heart
11) Confidence 0.57 Published 1986 Journal G Ital Cardiol Section Abstract Doc Link 3104124 Disease Relevance 0.13 Pain Relevance 0.21
In comparison with placebo maximal workload and total work performed were significantly higher on TTS NTG and on nifedipine at both times of observation, but no significant differences were seen after verapamil.
Gene_expression (higher) of NTG
12) Confidence 0.57 Published 1986 Journal G Ital Cardiol Section Abstract Doc Link 3104124 Disease Relevance 0.14 Pain Relevance 0.25
Since NTG is a chronically progressing disease, these findings imply that patients had NTG before BRVO, and correspond with the results of earlier studies.27
Gene_expression (disease) of NTG associated with low tension glaucoma, disease and retinal vein occlusion
13) Confidence 0.56 Published 2007 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2629887 Disease Relevance 2.56 Pain Relevance 0.12
Primary open angle glaucoma (POAG) and NTG appear to represent a continuum of open angle glaucoma in which the mechanism of glaucomatous optic neuropathy shifts from predominantly elevated intraocular pressure (IOP) in the former to additional IOP independent factors, i.e. a vascular ischemic effect in the latter, with considerable overlap of causative factors.6
Gene_expression (appear) of NTG in optic associated with low tension glaucoma, open-angle glaucoma, glaucoma, ocular hypertension and optic disorders
14) Confidence 0.56 Published 2007 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2629887 Disease Relevance 2.31 Pain Relevance 0.22
Since NTG is a chronically progressing disease, these findings imply that patients had NTG before BRVO, and correspond with the results of earlier studies.27
Gene_expression (imply) of NTG associated with low tension glaucoma, disease and retinal vein occlusion
15) Confidence 0.56 Published 2007 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2629887 Disease Relevance 2.60 Pain Relevance 0.15
However, the expression of only a small group of these genes (68) was modified by both treatments, indicating marked differences in the expressional effects of NTG and PETN.
Gene_expression (expressional) of NTG
16) Confidence 0.54 Published 2009 Journal Physiol. Genomics Section Abstract Doc Link 19417013 Disease Relevance 0.20 Pain Relevance 0.07
To analyze the expressional effects of NTG and PETN in a more comprehensive manner we performed whole genome expression profiling experiments using cardiac total RNA from NTG- or PETN-treated rats and DNA microarrays containing oligonucleotides representing 27,044 rat gene transcripts.
Spec (analyze) Gene_expression (expressional) of NTG
17) Confidence 0.54 Published 2009 Journal Physiol. Genomics Section Abstract Doc Link 19417013 Disease Relevance 0.26 Pain Relevance 0.09
We conclude from our observations that tolerance to transdermal NTG does not appear in veins, possibly due to the low plasma NTG concentrations produced by this preparation.
Gene_expression (produced) of NTG in plasma associated with transdermal and tolerance
18) Confidence 0.52 Published 1989 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2478766 Disease Relevance 0.06 Pain Relevance 0.58
Three minutes after in vivo NTG administration, concentration of NTG producing 50% reversal of aggregation (C50) increased from 7.9 +/- 1.9 x 10(-5) to 5.5 +/- 0.3 x 10(-4) M (p <0.01); this change persisted for at least 60 minutes.
Gene_expression (producing) of NTG
19) Confidence 0.52 Published 1997 Journal Am. J. Cardiol. Section Abstract Doc Link 9230146 Disease Relevance 0.27 Pain Relevance 0.44
Sodium nitroprusside and NTG produced significant reductions in blood flow to the maxilla, mandible, and tongue, while deep enflurane anesthesia did not.
Gene_expression (produced) of NTG in maxilla associated with anesthesia
20) Confidence 0.51 Published 1982 Journal J. Oral Maxillofac. Surg. Section Abstract Doc Link 6801227 Disease Relevance 0.27 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox